Clinical trials: Mesothelioma
Peritoneal Diseases
ERAS® Guidelines Validation of CRS With or Without HIPEC
Enhanced recovery after surgery (ERAS®) pathways have been shown to considerably reduce complications, length of stay and costs after most of surgical procedures by standardised application of best evidence-based perioperative…
- Trial name
- NCT05185791
- Testing
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 288 people
- Sponsor
- Hospices Civils de Lyon
Malignant Mesothelioma
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.
- Trial name
- NCT01649024
- Testing
- Tremelimumab
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
This phase II trial is study how well AZD2171 works in treating patients with malignant pleural mesothelioma that cannot be removed by surgery.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00243074
- Testing
- cediranib maleate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma; Lung
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
This is an open-label, non-randomized, phase II, single arm, multi-center controlled clinical trial. 47 patients will be enrolled in this trial to determine the efficacy and safety of Bintrafusp alfa (M7824) in advanced malignant…
- Trial name
- BIMES (NCT05005429)
- Testing
- Bintrafusp alfa
- Where
- 15 sites in Spain
- Volunteers
- 47 people
- Sponsor
- Fundación GECP
Pleural Effusion, Exudative Pleural Effusion
Forceps Versus Cryobiopsy in Undiagnosed Exudative Pleural Effusion Using Rigid Thoracoscopy
This study compared two ways of taking tissue samples from the lining of the lung (pleura) during rigid thoracoscopy in adults with pleural effusion of unknown cause: conventional forceps biopsy and cryobiopsy (freezing the…
- Conditions
- Pleural Effusion, Exudative Pleural Effusion, Mesothelioma
- Trial name
- NCT07869056
- Testing
- Pleural Cryobiopsy, Pleural Forceps Biopsy
- Where
- 2 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Ahmed Zakaria Elsaeed
Mesothelioma
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
- Trial name
- CheckMate743 (NCT02899299)
- Testing
- Nivolumab, Ipilimumab, Pemetrexed
- Where
- 109 sites in United States, Australia and 19 more
- Volunteers
- 605 people
- Sponsor
- Bristol-Myers Squibb
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma
Mesothelioma and Radical Surgery 2
Mesothelioma is a cancer of the thin membrane that lines the chest and abdomen. Around 2500 people in the UK are diagnosed with mesothelioma each year and the median survival is approximately 8.5 months.
- Trial name
- MARS2 (NCT02040272)
- Testing
- (Extended) pleurectomy decortication
- Where
- 25 sites in United Kingdom
- Volunteers
- 328 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Mesothelioma
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Background: Mesothelioma is a type of cancer. It originates in cells that line human body cavities. Most people have advanced disease when they are diagnosed. Researchers want to see if a combination of drugs can help.
- Trial name
- NCT04840615
- Testing
- LMB-100, ipilimumab, Diphenhydramine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
- Trial name
- NCT04162015
- Testing
- Nivolumab, Pemetrexed, Cisplatin or Carboplatin
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer, Head and Neck Cancer
Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology
This is an ancillary laboratory study to collect and bank blood and tissue samples. The biospecimens collected for this study will be invaluable for future research into predictive biomarkers and genomic alterations and their…
- Conditions
- Small Cell Lung Cancer, Head and Neck Cancer, Malignant Pleural Mesothelioma
- Trial name
- COMETH (NCT07550049)
- Testing
- Blood and Tissue Collection
- Volunteers
- 110 people
- Sponsor
- University of Kansas Medical Center
Mesothelioma, Malignant
11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)
Prospective exploratory study specifically investigating the role of 11C-Methionine PET/CT imaging in patients affected by Malignant Pleural Mesothelioma (MPM) and candidate to pleurodesis.
- Trial name
- NCT02519049
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Istituto Clinico Humanitas
Malignant Pleural Mesothelioma
Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma
MPM patients are not eligible for surgical procedures like decortication or pleuro-pneumectomy and have a median survival of 12 months with palliative chemotherapy.
- Trial name
- NCT01722149
- Testing
- Adoptive Transfer of re-directed T cells
- Where
- Switzerland
- Volunteers
- 4 people
- Sponsor
- University of Zurich
Epithelial Mesothelioma, Recurrent Malignant Mesothelioma
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
This phase II trial is studying how well sorafenib works in treating patients with malignant mesothelioma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood…
- Conditions
- Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma
- Trial name
- NCT00107432
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumor, Malignant Pleural Effusion
A Study of MT027 in Patients with Pleural Malignant Tumors
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who…
- Conditions
- Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma
- Trial name
- NCT06726564
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Advanced Esophageal Cancers, Primary Small Cell Lung Cancers
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
Background: Previously we have demonstrated induction of tumor antigen and tumor suppressor gene expression in lung cancer cells following exposure to the DNA demethylating agent, Decitabine (DAC).
- Conditions
- Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas
- Trial name
- NCT00037817
- Testing
- Decitabine, Depsipeptide, Celecoxib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelioma
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.
- Trial name
- NCT00407459
- Testing
- Bevacizumab, Pemetrexed, Carboplatin
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- Armando Santoro, MD
Cutaneous Melanoma, Pleural Mesothelioma
A Study of SGN-CD228A in Advanced Solid Tumors
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer
- Trial name
- NCT04042480
- Testing
- SGN-CD228A
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 88 people
- Sponsor
- Seagen Inc.
Mesothelioma
Studying the Clinical Trial Experiences of Patients With Mesothelioma
Medical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical study may make it more difficult for patients to take part or see it…
- Trial name
- NCT05819580
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Malignant (Pleural) Mesothelioma
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
Earlier the investigators determined the safety and feasibility of tumor lysate-pulsed dendritic cells as therapeutic adjuvants in mesothelioma patients.
- Trial name
- PMR-MM-002 (NCT01241682)
- Testing
- DC + CTX
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center